ChemoCentryx Inc.

14.37-0.6200-4.14%Vol 1.65M1Y Perf -73.03%
Jul 23rd, 2021 16:00 DELAYED
BID14.35 ASK14.45
Open15.00 Previous Close14.99
Pre-Market- After-Market14.37
 - -  - -%
Target Price
28.17 
Analyst Rating
Strong Buy 1.00
Potential %
96.03 
Finscreener Ranking
★★★     49.25
Insiders Trans % 3/6/12 mo.
-/-91/-93 
Value Ranking
★★+     49.56
Insiders Value % 3/6/12 mo.
67/-97/-98 
Growth Ranking
★+     43.04
Insiders Shares Cnt. % 3/6/12 mo.
63/-82/-90 
Income Ranking
 —    -
Market Cap1.00B 
Earnings Rating
Sell
Price Range Ratio 52W %
7.97 
Earnings Date
9th Aug 2021

Today's Price Range

14.3115.10

52W Range

9.5370.29

5 Year PE Ratio Range

-31.3040.80

Summary:

Sell

Technical Indicators: Neutral
Moving Averages: Strong Sell
Performance
1 Week
-9.34%
1 Month
10.03%
3 Months
-68.69%
6 Months
-77.69%
1 Year
-73.03%
3 Years
18.27%
5 Years
210.37%
10 Years
-

TickerPriceChg.Chg.%
CCXI14.37-0.6200-4.14
AAPL148.561.76001.20
GOOG2 756.3289.75003.37
MSFT289.673.53001.23
XOM57.04-0.0700-0.12
WFC44.59-0.4400-0.98
JNJ171.791.81001.06
FB369.7918.60005.30
GE12.710.01000.08
JPM150.64-0.2900-0.19
Financial StrengthValueIndustryS&P 500US Markets
7.10
7.10
0.14
0.19
-21.80
Leverage Ratio 1.40
ProfitabilityValueIndustryS&P 500US Markets
-
-88.10
-87.00
-131.30
-92.18
RevenueValueIndustryS&P 500US Markets
19.48M
0.28
-15.25
50.72
Earnings HistoryEstimateReportedSurprise %
Q01 2021-0.40-0.43-7.50
Q04 2020-0.32-0.43-34.38
Q03 2020-0.28-0.35-25.00
Q02 2020-0.340.29185.29
Q01 2020-0.30-0.35-16.67
Q04 2019-0.27-0.263.70
Q03 2019-0.28-0.2221.43
Q02 2019-0.21-0.26-23.81
Earnings Per EndEstimateRevision %Trend
6/2021 QR-0.55-12.24Negative
9/2021 QR-0.50-42.86Negative
12/2021 FY-1.93-26.14Negative
12/2022 FY-1.98-153.85Negative
Next Report Date9th Aug 2021
Estimated EPS Next Report-0.55
Estimates Count6
EPS Growth Next 5 Years %-
Volume Overview
Volume1.65M
Shares Outstanding69.75M
Trades Count14.34K
Dollar Volume32.55M
Avg. Volume2.31M
Avg. Weekly Volume1.65M
Avg. Monthly Volume3.88M
Avg. Quarterly Volume4.57M

ChemoCentryx Inc. (NASDAQ: CCXI) stock closed at 14.37 per share at the end of the most recent trading day (a -4.14% change compared to the prior day closing price) with a volume of 1.66M shares and market capitalization of 1.00B. Is a component of indices and it is traded on NASDAQ exchange. The company belongs in the Biotechnology industry, Healthcare sector and employs 82 people. ChemoCentryx Inc. CEO is Thomas J. Schall.

The one-year performance of ChemoCentryx Inc. stock is -73.03%, while year-to-date (YTD) performance is -76.79%. CCXI stock has a five-year performance of 210.37%. Its 52-week range is between 9.53 and 70.29, which gives CCXI stock a 52-week price range ratio of 7.97%

ChemoCentryx Inc. currently has a PE ratio of -17.00, a price-to-book (PB) ratio of 3.06, a price-to-sale (PS) ratio of 55.97, a price to cashflow ratio of 40.20, a PEG ratio of 2.32, a ROA of -17.88%, a ROC of -24.13% and a ROE of -29.83%. The company’s profit margin is -92.18%, its EBITDA margin is -87.00%, and its revenue ttm is $19.48 Million , which makes it $0.28 revenue per share.

Of the last four earnings reports from ChemoCentryx Inc., there were 1 positive earnings surprise and 3 negative earnings surprise. The company has EPS estimate of $-0.55 for the next earnings report. ChemoCentryx Inc.’s next earnings report date is 09th Aug 2021.

The consensus rating of Wall Street analysts for ChemoCentryx Inc. is Strong Buy (1), with a target price of $28.17, which is +96.03% compared to the current price. The earnings rating for ChemoCentryx Inc. stock is Sell (calculated from actual period earnings estimates revision (80% weight) and previous period earnings surprise (20% weight)).

ChemoCentryx Inc. has a dividend yield of -% with a dividend per share of $- and a payout ratio of -%.

ChemoCentryx Inc. has a Sell technical analysis rating based on Technical Indicators (ADX : 12.99, ATR14 : 1.12, CCI20 : -24.47, Chaikin Money Flow : 0.11, MACD : 0.19, Money Flow Index : 72.64, ROC : -0.69, RSI : 45.18, STOCH (14,3) : 23.68, STOCH RSI : 0.00, UO : 44.49, Williams %R : -76.32), Simple Moving Averages and Exponential Moving Averages.

Aggregated Insider Trades of ChemoCentryx Inc. in the last 12-months were: Geoffrey M. Parker (Option Excercise at a value of $0), Geoffrey M. Parker (Sold 31 910 shares of value $1 806 448 ), James L. Tyree (Option Excercise at a value of $0), James L. Tyree (Sold 2 454 shares of value $23 956 ), Markus J. Cappel (Option Excercise at a value of $467 906), Markus J. Cappel (Sold 44 792 shares of value $3 052 719 ), Pui San Kwan (Option Excercise at a value of $597 169), Pui San Kwan (Sold 62 428 shares of value $4 072 485 ), Rita I. Jain (Option Excercise at a value of $0), Susan M. Kanaya (Option Excercise at a value of $0), Tausif Butt (Buy at a value of $120 241), Thomas A. Edwards (Sold 46 500 shares of value $2 856 918 ), Thomas J. Schall (Option Excercise at a value of $411 727), Thomas J. Schall (Sold 28 772 shares of value $1 870 696 )

Analyst RatingsCurrent1 M ago3 M ago
Strong Buy
7 (100.00 %)
6 (100.00 %)
6 (100.00 %)
Moderate Buy
0 (0.00 %)
0 (0.00 %)
0 (0.00 %)
Hold
0 (0.00 %)
0 (0.00 %)
0 (0.00 %)
Moderate Sell
0 (0.00 %)
0 (0.00 %)
0 (0.00 %)
Strong Sell
0 (0.00 %)
0 (0.00 %)
0 (0.00 %)
Summary RatingStrong Buy
1.00
Strong Buy
1.00
Strong Buy
1.00

ChemoCentryx Inc.

ChemoCentryx Inc is a biopharmaceutical company involved in discovery, development, and commercialization of orally administered drugs to treat rare diseases, inflammatory disorders, autoimmune diseases, and cancer. The company's approach is to target the chemoattractant system, defined as a network of molecules (for example, chemokine ligands, their associated receptors, and chemoattractant receptors) known to cause inflammation. The targeted therapeutic areas are an antineutrophil cytoplasmic antibody, atypical hemolytic uremic syndrome, immunoglobulin A-mediated nephropathy (rare diseases category), pancreatic cancer, chronic kidney disease, psoriasis, rheumatoid arthritis, asthma, Crohn's disease, inflammatory bowel disease, and others.

CEO: Thomas J. Schall

Telephone: +1 650 210-2900

Address: 850 Maude Avenue, Mountain View 94043, CA, US

Number of employees: 82

Bearish or Bullish?
WeekMonthThree MonthsSix Months

Bearish Bullish

50%50%

Bearish Bullish

73%27%

Bearish Bullish

48%52%

Bearish Bullish

53%48%

News

Stocktwits